Elif ÜMİT, Hasan ÜMİT, Hasan GÖZE, Mehmet BAYSAL, Ahmet Muzaffer DEMİR

Reactivation of Hepatitis B Virus Infection 66 months after Rituximab Therapy for Chronic Lymphocytic Leukemia, Emphasis on Interplay between Infection, Drugs and Disease Biology

Hepatitis B virus (HBV) reactivation (HBVr) in patients receiving immunosuppression is an evolving topic. American Gastroenterology Association (AGA) have reported a guideline for the management of patients with certain HBV status who will undergo immunosuppression with regard to patient’s HBV status as well as the category and duration of immunosuppression. Here we are presenting a case with CLL who have received rituxmab with bendamustine 66 months before, developing HBVr with an emphasis on the discussion pathophysiological process of the disease itself, not just the treatment course. 59 years old male patient diagnosed with CLL and chronic asymptomatic HBV infection received 3 lines of treatment under viral prophylaxis in 13 years. 66 months after the last treatment with rituximab, HBV reactivation developed and treated with dual antiviral therapy. During this period a decrease in lymphocyte count was observed concurrent with transaminase elevation. As the reactivation was controlled, lymphocyte counts increased back to pre-flare levels. While the patient had impaired antibody related immune response since monoclonal B cells are nonfunctional, an attempt to improve T cell related response may be resulted with both to t he clearance of lymphocytes (as they were decreased) and the immune reaction of necroinflammation in the hepatocytes were triggered.

PDF

___

1. Coluccio C, Begini P, Marzano A, et al. Hepatitis B in patients with hematological diseases: An update. World J Hepatol 2017; 9: 1043-1053.

2. Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015; 148: 221-244.

3. Di Bisceglie AM, Lok AS, Martin P, et al. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology 2015; 61: 703-711.

4. Pel SN, Chen CH, Lee CM, Wand MC, Ma MC, Hu TH, Kuo CY. Reactivation of HepatitisB virus following rituximab based regimens aserious complication in both HbsAg positive and HbsAg negative patients. Ann Hematol 2010

5. Nakaya A, Fujita S, Satake A, et al. Delayed HBV reactivation in rituximab containing chemotherapy: How long should we continue anti-virus prophylaxis or monitoring HBV DNA? Leukemia Research 2016; 50: 46-49.

6. Muraishi J, Shibata M, Honma Y, et al. Reactivation of Occult Hepatitis B Virus Infection 27 Months after the End of Chemotherapy Including Rituximab for Malignant Lymphoma. Intern Med 2017; 56: 1967-1971.

7. Mozessohn L, Chan KK, Feld JJ, Hicks LK. Hepatitis B reactivation in HBsAgnegative/HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysis. J Viral Hepat 2015; 22: 842-849.

8. Yagci M, Suyani E, Cakar MK. The Impact of Chemotherapy on Hepatitis B antibody Titer in patients with Hematological Malignancies. Turkish Journal of Hematology 2015; 32: 251- 256.

9. Hwang JP, Suarez-Almazor ME, Cantor SB, et al. Impact of the timing of hepatitis B virus identification and anti-hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapy. Cancer 2017; 123: 3367-3376.